ESRRA

Across TCGA pan-cancer cohorts, ESRRA mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ESRRA data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ESRRA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ESRRA expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LSCC, and UCEC are the cancer types where ESRRA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.881	0.569	<.001	33	view →
LSCC	DFS	Tertile	All	0.999	0.893	.006	18	view →
UCEC	DFS	Median	All	0.963	0.876	.044	4	view →
LUAD	DFS	Median	All	0.829	0.669	.026	4	view →
HNSC	DFS	Quartile	All	0.720	0.900	.029	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ESRRA–CCRCC (DFS)

Open the CCRCC breakdown →